{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:36:35Z","timestamp":1792103795932,"version":"4.4.0"},"reference-count":44,"publisher":"China Science Publishing & Media Ltd.","issue":"4","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2025,4,1]]},"DOI":"10.3724\/abbs.2025027","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:51:23Z","timestamp":1740703883000},"page":"646-655","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Iron overload mediates cytarabine resistance in AML by                     inhibiting the TP53 signaling pathway"],"prefix":"10.3724","volume":"57","author":[{"given":"Yan","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunxun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"2196482","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"Mohamed Jiffry MZ","year":"2023","unstructured":"Mohamed Jiffry MZ, Kloss R, Ahmed-khan M, Carmona-Pires F, Okam N, Weeraddana P, Dharmaratna D. A review of treatment options employed in relapsed\/refractory AML. Hematology, 2023, 28:","journal-title":"Hematology"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1007\/s00277-023-05415-y","volume":"103","author":"Wei Z","year":"2024","unstructured":"Wei Z, Su L, Gao S. The roles of ubiquitination in AML. Ann Hematol, 2024, 103: 3413-3428.","journal-title":"Ann Hematol"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.3390\/jcm12206429","volume":"12","author":"Negotei C","year":"2023","unstructured":"Negotei C, Colita A, Mitu I, Lupu AR, Lapadat ME, Popovici CE, Crainicu M. A review of FLT3 kinase inhibitors in AML. J Clin Med, 2023, 12:","journal-title":"J Clin Med"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"2196482","DOI":"10.1002\/ijc.34684","volume":"28","author":"Jiffry MZ","year":"2023","unstructured":"Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, Dharmaratna D, Dandwani M, Moin K. A review of treatment options employed in relapsed\/refractory AML. Hematology, 2023, 28:","journal-title":"Hematology"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ijc.34684","volume":"154","author":"Allert C","year":"2024","unstructured":"Allert C, M\u00fcller-Tidow C, Blank MF. The relevance of the hematopoietic niche for therapy resistance                         in acute myeloid leukemia. Intl J Canc, 2024, 154: 197-209.","journal-title":"Intl J Canc"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood.2021014670","volume":"141","author":"Ediriwickrema A","year":"2023","unstructured":"Ediriwickrema A, Gentles AJ, Majeti R. Single-cell genomics in AML: extending the frontiers of AML                         research. Blood, 2023, 141: 345-355.","journal-title":"Blood"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1749-6632.2000.tb06705.x","volume":"910","author":"Soussi T","year":"2000","unstructured":"Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical                         investigation. Ann New                             York Acad Sci, 2000, 910: 121-137.","journal-title":"Ann New                             York Acad Sci"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"7621","DOI":"10.1038\/sj.onc.1203285","volume":"18","author":"May P","year":"1999","unstructured":"May P, May E. Twenty years of p53 research: structural and functional aspects                         of the p53 protein. Oncogene, 1999, 18: 7621-7636.","journal-title":"Oncogene"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"Levine AJ","year":"2009","unstructured":"Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Canc, 2009, 9: 749-758.","journal-title":"Nat Rev Canc"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jmb.2017.03.030","volume":"429","author":"Yue X","year":"2017","unstructured":"Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W. Mutant p53 in cancer: accumulation, gain-of-function, and therapy. J Mol Biol, 2017, 429: 1595-1606.","journal-title":"J Mol Biol"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"Muller PAJ","year":"2014","unstructured":"Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell, 2014, 25: 304-317.","journal-title":"Cancer Cell"},{"key":"CITATION12","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al.                         robertson a,genomic and epigenomic landscapes of adult de novo acute myeloid                         leukemia.                              N Engl J Med                          2013, 368:                         2059\u20132074."},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"Lindsley RC","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A. Acute myeloid leukemia ontogeny is defined by distinct somatic                         mutations. Blood, 2015, 125: 1367-1376.","journal-title":"Blood"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R. Molecular patterns of response and treatment failure after                         frontline venetoclax combinations in older patients with AML. Blood, 2020, 135: 791-803.","journal-title":"Blood"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"Wong TN","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, Lamprecht TL. Role of TP53 mutations in the origin and evolution of                         therapy-related acute myeloid leukaemia. Nature, 2015, 518: 552-555.","journal-title":"Nature"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/blood-2017-02-763086","volume":"130","author":"Prokocimer M","year":"2017","unstructured":"Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid                         leukemia: projections on diagnostic workup and therapy. Blood, 2017, 130: 699-712.","journal-title":"Blood"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","volume":"31","author":"Stengel A","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival                         varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia, 2017, 31: 705-711.","journal-title":"Leukemia"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","volume":"84","author":"Wattel E","year":"1994","unstructured":"Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P. p53 mutations are associated with resistance to chemotherapy and                         short survival in hematologic malignancies. Blood, 1994, 84: 3148-3157.","journal-title":"Blood"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exphem.2020.06.003","volume":"87","author":"Yan B","year":"2020","unstructured":"Yan B, Claxton D, Huang S, Qiu Y. AML chemoresistance: the role of mutant TP53 subclonal expansion                         and therapy strategy. Exp Hematol, 2020, 87: 13-19.","journal-title":"Exp Hematol"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/j.clinthera.2009.11.017","volume":"31","author":"Robak T","year":"2009","unstructured":"Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther, 2009, 31: 2349-2370.","journal-title":"Clin Ther"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"Nechiporuk T","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2032Alessandro A, Culp-Hill R. The TP53 apoptotic network is a primary mediator of resistance to                         BCL2 inhibition in AML cells. Cancer Discov, 2019, 9: 910-925.","journal-title":"Cancer Discov"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/gcc.22796","volume":"58","author":"Barbosa K","year":"2019","unstructured":"Barbosa K, Li S, Adams PD, Deshpande AJ. The role of TP53 in acute myeloid leukemia: challenges and                         opportunities. Genes Chromosomes Cancer, 2019, 58: 875-888.","journal-title":"Genes Chromosomes Cancer"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"Welch JS","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA, Fronick CC, O\u2019Laughlin M, Fulton RS, Wilson RK. TP53 and decitabine in acute myeloid leukemia                         and myelodysplastic syndromes. N Engl J Med, 2016, 375: 2023-2036.","journal-title":"N Engl J Med"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bjh.14455","volume":"176","author":"Chang C-","year":"2017","unstructured":"Chang C-, Zhao Y-, Xu F, Guo J, Zhang Z, He Q, Wu D. TP53 mutations predict decitabine-induced                         complete responses in patients with myelodysplastic syndromes. Br J Haematol, 2017, 176: 600-608.","journal-title":"Br J Haematol"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1080\/10428194.2020.1775210","volume":"61","author":"Walker JS","year":"2020","unstructured":"Walker JS, Garzon R, Lapalombella R. Selinexor for advanced hematologic malignancies. Leukemia                             Lymphoma, 2020, 61: 2335-2350.","journal-title":"Leukemia                             Lymphoma"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1134\/S0006297916060018","volume":"81","author":"Milto IV","year":"2016","unstructured":"Milto IV, Suhodolo IV, Prokopieva VD, Klimenteva TK. Molecular and cellular bases of iron metabolism in humans. Biochem Moscow, 2016, 81: 549-564.","journal-title":"Biochem Moscow"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3390\/ijms21062257","volume":"21","author":"Forciniti S","year":"2020","unstructured":"Forciniti S, Greco L, Grizzi F, Malesci A, Laghi L. Iron metabolism in cancer progression. Int J Mol Sci, 2020, 21:","journal-title":"Int J Mol Sci"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc3495","volume":"13","author":"Torti SV","year":"2013","unstructured":"Torti SV, Torti FM. Iron and cancer: More ore to be mined. Nat Rev Cancer, 2013, 13: 342-355.","journal-title":"Nat Rev Cancer"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/ijms20020273","volume":"20","author":"Jung M","year":"2019","unstructured":"Jung M, Mertens C, Tomat E, Br\u00fcne B. Iron as a central player and promising target in cancer                         progression. Int J Mol Sci, 2019, 20:","journal-title":"Int J Mol Sci"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s13238-014-0119-z","volume":"6","author":"Zhang C","year":"2015","unstructured":"Zhang C, Zhang F. Iron homeostasis and tumorigenesis: molecular mechanisms and                         therapeutic opportunities. Protein Cell, 2015, 6: 88-100.","journal-title":"Protein Cell"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00508-015-0842-3","volume":"127","author":"Ludwig H","year":"2015","unstructured":"Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M. Iron metabolism and iron supplementation in cancer patients. Wien Klin                             Wochenschr, 2015, 127: 907-919.","journal-title":"Wien Klin                             Wochenschr"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.7150\/thno.59092","volume":"11","author":"Morales M","year":"2021","unstructured":"Morales M, Xue X. Targeting iron metabolism in cancer therapy. Theranostics, 2021, 11: 8412-8429.","journal-title":"Theranostics"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41422-018-0090-y","volume":"28","author":"Zhou B","year":"2018","unstructured":"Zhou B, Zhang J, Liu X, Chen H, Ai Y, Cheng K, Sun R. Tom20 senses iron-activated ROS signaling to promote melanoma                         cell pyroptosis. Cell Res, 2018, 28: 1171-1185.","journal-title":"Cell Res"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.celrep.2014.02.042","volume":"7","author":"Shen J","year":"2014","unstructured":"Shen J, Sheng X, Chang ZN, Wu Q, Wang S, Xuan Z, Li D. Iron metabolism regulates p53 signaling through direct heme-p53                         interaction and modulation of p53 localization, stability, and function. Cell Rep, 2014, 7: 180-193.","journal-title":"Cell Rep"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"7674","DOI":"10.3390\/ijms21207674","volume":"21","author":"Calabrese C","year":"2020","unstructured":"Calabrese C, Panuzzo C, Stanga S, Andreani G, Ravera S, Maglione A, Pironi L. Deferasirox-dependent iron chelation enhances mitochondrial                         dysfunction and restores p53 signaling by stabilization of p53 family                         members in leukemic cells. Int J Mol Sci, 2020, 21:","journal-title":"Int J Mol Sci"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"100868","DOI":"10.1016\/j.mam.2020.100868","volume":"75","author":"Franke GN","year":"2020","unstructured":"Franke GN, Kubasch AS, Cross M, Vucinic V, Platzbecker U. Iron overload and its impact on outcome of patients with                         hematological diseases. Mol Aspects Med, 2020, 75:","journal-title":"Mol Aspects Med"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1182\/asheducation-2008.1.166","volume":"2008","author":"Cazzola M","year":"2008","unstructured":"Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in                         myelodysplastic syndromes. Hematology, 2008, 2008: 166-175.","journal-title":"Hematology"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"Eskelund CW","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP. TP53 mutations identify younger mantle cell lymphoma patients who                         do not benefit from intensive chemoimmunotherapy. Blood, 2017, 130: 1903-1910.","journal-title":"Blood"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","volume":"2","author":"Bosc C","year":"2021","unstructured":"Bosc C, Saland E, Bousard A, Gadaud N, Sabatier M, Cognet G, Farge T. Mitochondrial inhibitors circumvent adaptive resistance to                         venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nat Cancer, 2021, 2: 1204-1223.","journal-title":"Nat Cancer"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"Zhang C","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug                         resistance. Mol Cancer, 2022, 21:","journal-title":"Mol Cancer"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1016\/j.celrep.2020.02.049","volume":"30","author":"Feng H","year":"2020","unstructured":"Feng H, Schorpp K, Jin J, Yozwiak CE, Hoffstrom BG, Decker AM, Rajbhandari P. Transferrin receptor is a specific ferroptosis marker. Cell Rep, 2020, 30: 3411-3423.e7.","journal-title":"Cell Rep"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cmet.2009.04.005","volume":"9","author":"Roodman GD","year":"2009","unstructured":"Roodman GD. Osteoclasts pump iron. Cell Metab, 2009, 9: 405-406.","journal-title":"Cell Metab"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clinbiochem.2015.07.099","volume":"49","author":"Wieland E","year":"2016","unstructured":"Wieland E, Shipkova M. Lymphocyte surface molecules as immune activation biomarkers. Clin                             Biochem, 2016, 49: 347-354.","journal-title":"Clin                             Biochem"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2018.06.037","volume":"133","author":"Kawabata H","year":"2019","unstructured":"Kawabata H. Transferrin and transferrin receptors update. Free                             Radical Biol Med, 2019, 133: 46-54.","journal-title":"Free                             Radical Biol Med"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/343AFE026A34423FB3B4112DB9E22E1C","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025027","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/343AFE026A34423FB3B4112DB9E22E1C","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T02:57:39Z","timestamp":1757645859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2025027","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}